Myriad Genetics, Inc

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°C

SBTI ID

40020670

Informations générales

Localisation

United States of America

Northern America

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

27/11/2025

Objectifs à court terme (Near-Term)

Engagement de réduction des émissions à horizon 2035

Statut

Targets set

Classification

1.5°C

Année cible

2035

Progression vers l'objectif55%

2015 (année de référence)2035

Description complète des objectifs

Near-Term Targets: Myriad Genetics, Inc commits to reduce absolute scope 1 and 2 GHG emissions 63.0% by 2035 from a 2024 base year. Myriad Genetics, Inc also commits to reduce scope 3 GHG emissions from purchased goods and services and fuel- and energy-related activities 66.33% per USD value added within the same timeframe.

Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Source : Science Based Targets initiative | Données publiques